Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

Table 13 Non-invasive tools for liver disease severity assessment of non-acute and acute decompensating patients

Variables (mean ± SD)	NAD-decompensating patients (n = 29)	AD-decompensating patients (n = 14)	P value1
LSM (kPa)	20.90 ± 2.09	28.04 ± 3.44	< 0.0001
APRI	1.60 ± 0.30	1.90 ± 0.38	< 0.0001
FIB-4	3.53 ± 1.75	3.86 ± 2.64	NS
ALBI	-1.98 ± 0.62	-1.66 ± 0.35	0.03
Child-Pugh	6.89 ± 0.97	7.42 ± 0.75	0.046
MELD	11.07 ± 3.35	13.79 ± 2.07	0.011
RDW (fL)/PLT ratio	0.668 ± 0.152	1.077 ± 0.253	< 0.0001

¹Mann-Whitney U test.

Statistically significant differences (P < 0.05) are reported in bold. LSM: Liver stiffness measurement; APRI: Aspartate aminotransferase/platelet count ratio index; MELD: Model for End-stage Liver Disease FIB-4: Fibrosis-4; NS: Not statistically significant; AD: Acute decompensation; NAD: Non-acute decompensation.